Company / SG&A Expense
Amgen SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$7.0B
FY2025
5-year range
$5.4B / $7.1B
FY2021-FY2025
Trend
-0.6%
vs FY2024
Sector context
#7 of 211
Health Care
What the data says
Among 211 Health Care companies, Amgen is in the bottom 3% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $4.9B in FY2017 to $7.1B in FY2024.
Based on SEC 10-K filings.
$7.0B in FY2025 with a 5-year CAGR of +4.2%. Top quartile in the Health Care sector.
Increased from $6.2B to $7.0B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 211This company $7.0B Sector average $728.7M
▼
+867.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.6% year-over-year.
- Ranks #7 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.0B | -0.6% |
| FY2024 | $7.1B | +14.8% |
| FY2023 | $6.2B | +14.1% |
| FY2022 | $5.4B | +0.9% |
| FY2021 | $5.4B | -6.3% |
| FY2020 | $5.7B | +11.3% |
| FY2019 | $5.2B | -3.4% |
| FY2018 | $5.3B | +9.5% |
| FY2017 | $4.9B | -3.8% |
| FY2016 | $5.1B | +4.5% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026